Loading the section…

IMCR: financial statements from SEC — TradeAlmanac

IMCR

Immunocore Holdings plc: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	107M	104M	98M	94M	80M	75M
Cost of revenue	434,000	513,000	1M	831,000	448,000	2M
Research and development	61M	71M	69M	56M	53M	51M
Selling, general and administrative	38M	40M	43M	40M	36M	39M
Operating income	7M	−7M	−15M	−4M	−9M	−16M
Pre-tax income	13M	304,000	−10M	6M	6M	−10M
Income tax	301,000	481,000	606,000	1M	−3M	1M
Net income	13M	−177,000	−10M	5M	9M	−12M
Earnings per share	0.26	0.00	−0.20	0.10	0.17	−0.23
Earnings per share, diluted	0.25	0.00	−0.20	0.10	0.17	−0.23
Weighted average shares	51M	50M	50M	50M	50M	50M
Weighted average shares, diluted	53M	50M	50M	52M	53M	50M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	453M	468M	498M	488M	477M	456M	538M	505M
Short-term investments	392M	396M	394M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−14M	435,000
Depreciation and amortisation	948,000	854,000
Share-based compensation	6M	9M
Capital expenditure	2M	298,000
Investing cash flow	4M	10M
Financing cash flow	656,000

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator